Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain. METHODS: Patients were enrolled after they had undergone a coronary stent procedure in which a drug-eluting stent was placed. After 12 months of treatment with a thienopyridine drug (clopidogrel or prasugrel) and aspirin, patients were randomly assigned to continue receiving thienopyridine treatment or to receive placebo for another 18 months; all patients continued receiving aspirin. The coprimary efficacy end points were stent thrombosis and major adverse cardiovascular and cerebrovascular events (a composite of death, myocardial infarction, or stroke) during the period from 12 to 30 months. The primary safety end point was moderate or severe bleeding. RESULTS: A total of 9961 patients were randomly assigned to continue thienopyridine treatment or to receive placebo. Continued treatment with thienopyridine, as compared with placebo, reduced the rates of stent thrombosis (0.4% vs. 1.4%; hazard ratio, 0.29 [95% confidence interval {CI}, 0.17 to 0.48]; P<0.001) and major adverse cardiovascular and cerebrovascular events (4.3% vs. 5.9%; hazard ratio, 0.71 [95% CI, 0.59 to 0.85]; P<0.001). The rate of myocardial infarction was lower with thienopyridine treatment than with placebo (2.1% vs. 4.1%; hazard ratio, 0.47; P<0.001). The rate of death from any cause was 2.0% in the group that continued thienopyridine therapy and 1.5% in the placebo group (hazard ratio, 1.36 [95% CI, 1.00 to 1.85]; P=0.05). The rate of moderate or severe bleeding was increased with continued thienopyridine treatment (2.5% vs. 1.6%, P=0.001). An elevated risk of stent thrombosis and myocardial infarction was observed in both groups during the 3 months after discontinuation of thienopyridine treatment. CONCLUSIONS: Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding. (Funded by a consortium of eight device and drug manufacturers and others; DAPT ClinicalTrials.gov number, NCT00977938.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, the reporting and interpretation of the risk of all-cause mortality in the DAPT (dual antiplatelet therapy) study randomizing 9,961 patients to continue DAPT beyond 1 y after stent placement or receive a placebo for 30 mo, raised some concerns (24, 25).”
From Misrepresentation and distortion of research in biomedical literature (2018) · cites this paper as [24]
In the citing paper
“Large observational studies or head-to-head RCTs show similar rates of gastrointestinal and non-gastrointestinal major bleeding for single antiplatelet therapy (SAPT) with low-dose ASA or a P2Y 12 inhibitor (clopidogrel or ticagrelor).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Regarding CV safety, the composite of MI, stroke, CV death, CHD, and acute limb ischaemia was similar between pantoprazole and placebo, as was the rate of new-onset diabetes.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Thus, gastrointestinal mucosal bleeding appears to be due to pre-existing mucosal lesions associated with defective primary haemostasis secondary to platelet inhibition, rather than with a specific antiplatelet drug.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Combined antithrombotic drugs, while effective, increase major bleeding risk.337,338”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citationPrasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citation(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationHeart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Mehran, R., Rao, S. V., Bhatt, D. L., Gibson, C. M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S. D., Menon, V., Nikolsky, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.009449 · Cited by 4,476
Self-citation(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
Research works printed but not linked: 1
- Feres F, 2013, JAMA, 310, 2510
Cited by
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citation2018 ESC/EACTS guidelines on myocardial revascularization
Neumann, F.-J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy394 · Cited by 7,167
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R. F., Deaton, C., Cuisset, T., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz425 · Cited by 7,166
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333
Collet, J.-P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa575 · Cited by 5,037
Self-citationCosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Valgimigli, M., Bueno, H., Byrne, R. A., Collet, J.-P., Costa, F., Jeppsson, A., Jüni, P., Kastrati, A., Kolh, P., Mauri, L., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx419 · Cited by 2,987
Self-citation2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C., Andreotti, F., Koskinas, K. C., Rossello, X., Adamo, M., Ainslie, J., Banning, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 2,774
Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
“Current ACS guidelines recommend DAPT for up to 1 year after the acute event in patients without indication for OAC, while high-risk patients might require an even longer DAPT duration.(318,319) They do, however, also allow for shorter DAPT durations (3–6 months) in high bleeding risk ACS patients.”
BackgroundLong-term use of ticagrelor in patients with prior myocardial infarction
Bonaca, M. P., Bhatt, D. L., Cohen, M., Steg, P. G., Storey, R. F., Jensen, E. C., Magnani, G., Bansilal, S., Fish, M. P., Im, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500857 · Cited by 1,999
Self-citation2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Levine, G. N., Bates, E. R., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., Granger, C. B., Lange, R. A., Mack, M. J., Mauri, L., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.513 · Cited by 1,641
“The impetus for this focused update review is 11 s tudies (16-27) of patients treated with coronary st ent implantation (predominantly with drug -eluting stents [DES]) assessing shorter-duration or longer-duration DAPT, as well as a large, randomized controlled tri al (RCT) of patients 1 to 3 years after myocardial in…”
BackgroundMethodInfluentialSelf-citationReed, G. W., Rossi, J. E., & Cannon, C. P. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30677-8 · Cited by 1,507
Levine, G. N., Bates, E. R., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., Granger, C. B., Lange, R. A., Mack, M. J., Mauri, L., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000404 · Cited by 1,355
Self-citationAuthors/Task Force Members, Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316653709 · Cited by 1,334
2018 ESC/EACTS Guidelines on myocardial revascularization
Neumann, F.-J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2019) · EuroIntervention · doi:10.4244/eijy19m01_01 · Cited by 1,259
Costa, F., van Klaveren, D., James, S., Heg, D., Räber, L., Feres, F., Pilgrim, T., Hong, M.-K., Kim, H.-S., Colombo, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30397-5 · Cited by 1,184
Self-citationLow Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2015) · Europace · doi:10.1093/europace/euv309 · Cited by 1,113
Ticagrelor with or without Aspirin in High-Risk Patients after PCI
Mehran, R., Baber, U., Sharma, S. K., Cohen, D. J., Angiolillo, D. J., Briguori, C., Cha, J. Y., Collier, T., Dangas, G., Dudek, D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908419 · Cited by 1,039
Self-citation2018 ESC/EACTS Guidelines on myocardial revascularization
Sousa-Uva, M., Neumann, F.-J., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2019) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezy289 · Cited by 989
Yeh, R. W., Secemsky, E. A., Kereiakes, D. J., Normand, S.-L. T., Gershlick, A. H., Cohen, D. J., Spertus, J. A., Steg, P. G., Cutlip, D. E., Rinaldi, M. J., et al. (2016) · JAMA · doi:10.1001/jama.2016.3775 · Cited by 934
“Two forms of validation were conducted: (1) evaluation of the DAPT Study–derived ischemic and bleeding models and (2) evaluation of prediction score performance in stratifying risks of ischemic and bleeding events.”
MethodSelf-citationWatanabe, H., Domei, T., Morimoto, T., Natsuaki, M., Shiomi, H., Toyota, T., Ohya, M., Suwa, S., Takagi, K., Nanasato, M., et al. (2019) · JAMA · doi:10.1001/jama.2019.8145 · Cited by 857
Urban, P., Mehran, R., Colleran, R., Angiolillo, D. J., Byrne, R. A., Capodanno, D., Cuisset, T., Cutlip, D., Eerdmans, P., Eikelboom, J., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.040167 · Cited by 823
Self-citationPolymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk
Urban, P., Meredith, I. T., Abizaid, A., Pocock, S. J., Carrié, D., Naber, C., Lipiecki, J., Richardt, G., Iñiguez, A., Brunel, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503943 · Cited by 818
Vranckx, P., Valgimigli, M., Jüni, P., Hamm, C., Steg, P. G., Heg, D., van Es, G. A., McFadden, E. P., Onuma, Y., van Meijeren, C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31858-0 · Cited by 791
Self-citationThe Platelet Lifeline to Cancer: Challenges and Opportunities
Haemmerle, M., Stone, R. L., Menter, D. G., Afshar-Kharghan, V., & Sood, A. K. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.002 · Cited by 638
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001309 · Cited by 625
Urban, P., Mehran, R., Colleran, R., Angiolillo, D. J., Byrne, R. A., Capodanno, D., Cuisset, T., Cutlip, D., Eerdmans, P., Eikelboom, J., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz372 · Cited by 621
Self-citationByrne, R. A., Joner, M., & Kastrati, A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv511 · Cited by 609
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · JACC · doi:10.1016/j.jacc.2024.11.009 · Cited by 552
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab154 · Cited by 542
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.05.037 · Cited by 486
Ibánez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.11.010 · Cited by 461
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2015) · Kardiologia Polska · doi:10.5603/kp.2015.0243 · Cited by 458
Généreux, P., Giustino, G., Witzenbichler, B., Weisz, G., Stuckey, T. D., Rinaldi, M. J., Neumann, F.-J., Metzger, D. C., Henry, T. D., Cox, D. A., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.1323 · Cited by 454
“Our study has several strengths relative to prior similar investigations, including its large size, prospective nature, recruitment of an allcomers population (resulting in higher PDB rates than in previous studies) (4,10), and assessment of platelet reactivity to aspirin and clopidogrel.”
BackgroundResultSelf-citationEfficacy and Safety of Dual Antiplatelet Therapy After Complex PCI
Giustino, G., Chieffo, A., Palmerini, T., Valgimigli, M., Feres, F., Abizaid, A., Costa, R. A., Hong, M.-K., Kim, B.-K., Jang, Y., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.07.760 · Cited by 454
Fiedler, K. A., Maeng, M., Mehilli, J., Schulz-Schüpke, S., Byrne, R. A., Sibbing, D., Hoppmann, P., Schneider, S., Fusaro, M., Ott, I., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.050 · Cited by 443
“Additionally, the optimal duration of clopidogrel therapy after DES implantation in patients not receiving OAC has shown no uniform results (18,19).”
BackgroundBioresorbable Scaffolds versus Metallic Stents in Routine PCI
Wykrzykowska, J. J., Kraak, R. P., Hofma, S. H., van der Schaaf, R. J., Arkenbout, E. K., IJsselmuiden, A. J., Elias, J., van Dongen, I. M., Tijssen, R. Y. G., Koch, K. T., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614954 · Cited by 441
Schulz-Schupke, S., Byrne, R. A., ten Berg, J. M., Neumann, F.-J., Han, Y., Adriaenssens, T., Tolg, R., Seyfarth, M., Maeng, M., Zrenner, B., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu523 · Cited by 431
Valgimigli, M., Bueno, H., Byrne, R. A., Collet, J.-P., Costa, F., Jeppsson, A., Jüni, P., Kastrati, A., Kolh, P., Mauri, L., et al. (2018) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezx334 · Cited by 409
Self-citationMalehmir, M., Pfister, D., Gallage, S., Szydlowska, M., Inverso, D., Kotsiliti, E., Leone, V., Peiseler, M., Surewaard, B. G. J., Rath, D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0379-5 · Cited by 398
Palmerini, T., Benedetto, U., Bacchi-Reggiani, L., Riva, D. D., Biondi-Zoccai, G., Feres, F., Abizaid, A., Hong, M.-K., Kim, B.-K., Jang, Y., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60263-x · Cited by 396
Varenne, O., Cook, S., Sideris, G., Kedev, S., Cuisset, T., Carrié, D., Hovasse, T., Garot, P., El Mahmoud, R., Spaulding, C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32713-7 · Cited by 392
Hahn, J.-Y., Song, Y. B., Oh, J.-H., Cho, D.-K., Lee, J. B., Doh, J.-H., Kim, S.-H., Jeong, J.-O., Bae, J.-H., Kim, B.-O., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30493-8 · Cited by 372
Udell, J. A., Bonaca, M. P., Collet, J.-P., Lincoff, A. M., Kereiakes, D. J., Costa, F., Lee, C. W., Mauri, L., Valgimigli, M., Park, S.-J., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv443 · Cited by 370
“After exclusions, the remaining six trials met criteria for eligibility in the primary meta-analysis.(17,18,23) – 29 These trials, which comprised 33 435 participants randomized to a strategy of extended DAPT (n 1⁄4 20 203) vs.”
BackgroundMethodSelf-citationKoo, B.-K., Kang, J., Park, K. W., Rhee, T.-M., Yang, H.-M., Won, K.-B., Rha, S.-W., Bae, J.-W., Lee, N. H., Hur, S.-H., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01063-1 · Cited by 370
ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy
Capodanno, D., Alfonso, F., Levine, G. N., Valgimigli, M., & Angiolillo, D. J. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.057 · Cited by 366
Ticagrelor in patients with stable coronary disease and diabetes
Steg, P. G., Bhatt, D. L., Simon, T., Fox, K., Mehta, S. R., Harrington, R. A., Held, C., Andersson, M., Himmelmann, A., Ridderstråle, W., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908077 · Cited by 365
Self-citationJCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease
Nakamura, M., Kimura, K., Kimura, T., Ishihara, M., Otsuka, F., Kozuma, K., Kosuge, M., Shinke, T., Nakagawa, Y., Natsuaki, M., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-19-1109 · Cited by 352
Johansson, S., Rosengren, A., Young, K., & Jennings, E. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0482-9 · Cited by 344
“In the DAPT study in patients treated with a drug-eluting stent, of whom 31% presented with AMI, prolonged DAPT beyond 12 months significantly lowered the cumulative incidence of stent thrombosis and of major CV and cerebrovascular events during the subsequent 18 months compared with acetylsalicylic acid alone [25].”
BackgroundDuration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation
Giustino, G., Baber, U., Sartori, S., Mehran, R., Mastoris, I., Kini, A. S., Sharma, S. K., Pocock, S. J., & Dangas, G. D. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.01.039 · Cited by 344
“Considering the marked differences in trial size and reported outcomes of the recent DAPT trial (7), the study-specific influence on primary outcomes was estimated after removal of this trial from the”
BackgroundMethodInfluentialValgimigli, M., Costa, F., Lokhnygina, Y., Clare, R. M., Wallentin, L., Moliterno, D. J., Armstrong, P. W., White, H. D., Held, C., Aylward, P. E., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw525 · Cited by 330
“In light of recent clinical trial data with DAPT regimens beyond 1 year showing further reduction of ischaemic events at the price of a similar increase in bleeding, the number of patients who may qualify for longer-term DAPT is going to increase.(14,15) Therefore, it is critical to understand the prognostic implicati…”
Navarese, E. P., Andreotti, F., Schulze, V., Ko odziejczak, M., Buffon, A., Brouwer, M., Costa, F., Kowalewski, M., Parati, G., Lip, G. Y. H., et al. (2015) · BMJ · doi:10.1136/bmj.h1618 · Cited by 330
“10 Thus, the optimal duration of dual antiplatelet therapy is debated, with short term and extended protocols not yet compared to standard 12 month treatment within the same trial.”
Xu, X. R., Yousef, G. M., & Ni, H. (2018) · Blood · doi:10.1182/blood-2017-05-743187 · Cited by 325
Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting
Costa, F., Van Klaveren, D., Feres, F., James, S., Räber, L., Pilgrim, T., Hong, M.-K., Kim, H.-S., Colombo, A., Steg, P. G., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.048 · Cited by 325
Self-citationCoronary Artery Disease in Patients ≥80 Years of Age
Madhavan, M. V., Gersh, B. J., Alexander, K. P., Granger, C. B., & Stone, G. W. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.12.068 · Cited by 320
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2024) · European Heart Journal: Acute Cardiovascular Care · doi:10.1093/ehjacc/zuad107 · Cited by 314
Chew, D. P., Scott, I. A., Cullen, L., French, J. K., Briffa, T. G., Tideman, P. A., Woodruffe, S., Kerr, A., Branagan, M., & Aylward, P. E. G. (2016) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2016.06.789 · Cited by 314
Levine, G. N., Bates, E. R., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., Granger, C. B., Lange, R. A., Mack, M. J., Mauri, L., et al. (2016) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2016.07.044 · Cited by 304
“, sirolimus- and paclitaxel-eluting) DES, which are rarely, if ever, used in current clinical practice (16,36,38).”
BackgroundInfluentialSelf-citationArnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo, D. A., Galli, M., Collet, J.-P., Kastrati, A., & O'Donoghue, M. O. (2022) · EuroIntervention · doi:10.4244/eij-d-21-00904 · Cited by 299
Mega, J. L., & Simon, T. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60243-4 · Cited by 284
Yeh, R. W., Kereiakes, D. J., Steg, P. G., Windecker, S., Rinaldi, M. J., Gershlick, A. H., Cutlip, D. E., Cohen, D. J., Tanguay, J.-F., Jacobs, A., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.003 · Cited by 276
“As previously described (1), a higher rate of non-cardiovascular death was observed among drug-”
InfluentialSelf-citationMisrepresentation and distortion of research in biomedical literature
Boutron, I., & Ravaud, P. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710755115 · Cited by 273
Macle, L., Cairns, J., Leblanc, K., Tsang, T., Skanes, A., Cox, J. L., Healey, J. S., Bell, A., Pilote, L., Andrade, J. G., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.591 · Cited by 272
Stone, G. W., Gao, R., Kimura, T., Kereiakes, D. J., Ellis, S. G., Onuma, Y., Cheong, W.-F., Jones-McMeans, J., Su, X., Zhang, Z., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01039-9 · Cited by 266
Self-citationAntithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease
(2019) · New England Journal of Medicine · doi:10.1056/nejmc1914049 · Cited by 260
Kereiakes, D. J., Meredith, I. T., Windecker, S., Lee Jobe, R., Mehta, S. R., Sarembock, I. J., Feldman, R. L., Stein, B., Dubois, C., Grady, T., et al. (2015) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.114.002372 · Cited by 246
“additional ischemic event reduction.(6) The SYNERGY stent”
Self-citation2020 Clinical practice guidelines for Stable coronary artery disease
Russian Society of Cardiology (RSC) (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-4076 · Cited by 242
Andreotti, F., Rocca, B., Husted, S., Ajjan, R. A., ten Berg, J., Cattaneo, M., Collet, J.-P., De Caterina, R., Fox, K. A. A., Halvorsen, S., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv304 · Cited by 241
“Optimal duration of dual antiplatelet therapy (DAPT) with contemporary stenting is a matter of debate.(73,74) The recent”
BackgroundResultEvidence Review Committee Members, Bittl, J. A., Baber, U., Bradley, S. M., & Wijeysundera, D. N. (2016) · Circulation · doi:10.1161/cir.0000000000000405 · Cited by 227
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis
Patrono, C., Morais, J., Baigent, C., Collet, J.-P., Fitzgerald, D., Halvorsen, S., Rocca, B., Siegbahn, A., Storey, R. F., & Vilahur, G. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.037 · Cited by 221
Mehta, S. R., Bainey, K. R., Cantor, W. J., Lordkipanidzé, M., Marquis-Gravel, G., Robinson, S. D., Sibbald, M., So, D. Y., Wong, G. C., Abunassar, J. G., et al. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.012 · Cited by 211
Matsumura-Nakano, Y., Shizuta, S., Komasa, A., Morimoto, T., Masuda, H., Shiomi, H., Goto, K., Nakai, K., Ogawa, H., Kobori, A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.036768 · Cited by 207
Palmerini, T., Della Riva, D., Benedetto, U., Bacchi Reggiani, L., Feres, F., Abizaid, A., Gilard, M., Morice, M.-C., Valgimigli, M., Hong, M.-K., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehw627 · Cited by 201
Natsuaki, M., Morimoto, T., Yamaji, K., Watanabe, H., Yoshikawa, Y., Shiomi, H., Nakagawa, Y., Furukawa, Y., Kadota, K., Ando, K., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008708 · Cited by 195
“P rolonged duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) was shown to significantly reduce the risk of myocardial infarction (MI) and stent thrombosis (ST) compared with aspirin monotherapy in the DAPT (Dual Antiplatelet Therapy) trial.(1) However, prolonged DAPT was also…”
MethodBittl, J. A., Baber, U., Bradley, S. M., & Wijeysundera, D. N. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.512 · Cited by 194
Iliescu, C. A., Grines, C. L., Herrmann, J., Yang, E. H., Cilingiroglu, M., Charitakis, K., Hakeem, A., Toutouzas, K. P., Leesar, M. A., & Marmagkiolis, K. (2016) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26379 · Cited by 190
“However, the recently reported DAPT study suggests that patients treated with either BMS or DES may benefit from 30 weeks of therapy [202], although it is unclear whether a patient population with cancer or ultrasound-guided stent placement would derive a similar benefit.”
BackgroundAli, Z. A., Gao, R., Kimura, T., Onuma, Y., Kereiakes, D. J., Ellis, S. G., Chevalier, B., Vu, M.-T., Zhang, Z., Simonton, C. A., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.031843 · Cited by 189
Self-citationDe Luca, G., Damen, S. A., Camaro, C., Benit, E., Verdoia, M., Rasoul, S., Liew, H. B., Polad, J., Ahmad, W. A., Zambahari, R., et al. (2019) · EuroIntervention · doi:10.4244/eij-d-19-00539 · Cited by 187
Iliescu, C., Grines, C. L., Herrmann, J., Yang, E. H., Cilingiroglu, M., Charitakis, K., Hakeem, A., Toutouzas, K., Leesar, M. A., & Marmagkiolis, K. (2016) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26375 · Cited by 186
Updates on Acute Coronary Syndrome: A Review
Eisen, A., Giugliano, R. P., & Braunwald, E. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.2049 · Cited by 185
Self-citationKedhi, E., Fabris, E., van der Ent, M., Buszman, P., von Birgelen, C., Roolvink, V., Zurakowski, A., Schotborgh, C. E., Hoorntje, J. C. A., Eek, C. H., et al. (2018) · BMJ · doi:10.1136/bmj.k3793 · Cited by 184
Khan, S. U., Singh, M., Valavoor, S., Khan, M. U., Lone, A. N., Khan, M. Z., Khan, M. S., Mani, P., Kapadia, S. R., Michos, E. D., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046308 · Cited by 183
Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis
Li, X., Weber, N. C., Cohn, D. M., Hollmann, M. W., DeVries, J. H., Hermanides, J., & Preckel, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112419 · Cited by 181
“Due to the prothrombotic state and enhanced cardiovascular risk in diabetic patients, the necessity of antiplatelet and anticoagulation therapy is well acknowledged, but the optimal treatment strategies remain controversial [78,79].”
BackgroundCapodanno, D., Mehran, R., Krucoff, M. W., Baber, U., Bhatt, D. L., Capranzano, P., Collet, J.-P., Cuisset, T., De Luca, G., De Luca, L., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.064473 · Cited by 179
Self-citationTicagrelor With or Without Aspirin After Complex PCI
Dangas, G., Baber, U., Sharma, S. K., Giustino, G., Mehta, S. R., Cohen, D. J., Angiolillo, D. J., Sartori, S., Chandiramani, R., Briguori, C., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.011 · Cited by 179
Self-citationHelft, G., Steg, P. G., Le Feuvre, C., Georges, J.-L., Carrie, D., Dreyfus, X., Furber, A., Leclercq, F., Eltchaninoff, H., Falquier, J.-F., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv481 · Cited by 177
Self-citationChiarito, M., Sanz-Sánchez, J., Cannata, F., Cao, D., Sturla, M., Panico, C., Godino, C., Regazzoli, D., Reimers, B., De Caterina, R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30315-9 · Cited by 174
2024 Clinical practice guidelines for Stable coronary artery disease
Барбараш, О. Л., Karpov, Y. A., Panov, A. V., Akchurin, R. S., Alekyan, B. G., Alekhin, M. N., Aronov, D. M., HARUTYUNYAN, G., Belenkov, Y. N., Boytsov, S. A., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6110 · Cited by 182
Short- Versus Long-Term Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation
Palmerini, T., Sangiorgi, D., Valgimigli, M., Biondi-Zoccai, G., Feres, F., Abizaid, A., Costa, R. A., Hong, M.-K., Kim, B.-K., Jang, Y., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.12.046 · Cited by 171
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Hæusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab157 · Cited by 171
Nicolau, J. C., Feitosa, G. S., Petriz, J. L. F., Furtado, R. H. D. M., Précoma, D. B., Lemke, W., Lópes, R. D., Timerman, A., Marin‐Neto, J. A., Bezerra, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210180 · Cited by 322
Long-Term Evolution of Premature Coronary Artery Disease
Collet, J.-P., Zeitouni, M., Procopi, N., Hulot, J.-S., Silvain, J., Kerneis, M., Thomas, D., Lattuca, B., Barthelemy, O., Lavie-Badie, Y., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.1002 · Cited by 169
Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis
Elmariah, S., Mauri, L., Doros, G., Galper, B. Z., O'Neill, K. E., Steg, P. G., Kereiakes, D. J., & Yeh, R. W. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62052-3 · Cited by 168
Self-citation
Metadata
- Authors
- Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., Normand, S.-L. T., Braunwald, E., Wiviott, S. D., Cohen, D. J., Holmes, D. R., Krucoff, M. W., Hermiller, J., Dauerman, H. L., Simon, D. I., Kandzari, D. E., Garratt, K. N., Lee, D. P., Pow, T. K., Ver Lee, P., Rinaldi, M. J., & Massaro, J. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Christ Hospital (US)
- Harvard University (US)
- Beth Israel Deaconess Medical Center (US)
- University of Missouri–Kansas City (US)
- Duke Medical Center (US)
- St Vincent Hospital (US)
- University of Vermont (US)
- University Hospitals Cleveland Medical Center (US)
- Piedmont Atlanta Hospital (US)
- Lenox Hill Hospital (US)
- Stanford University (US)
- Carolinas Healthcare System (US)
- Boston University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-04
- Volume
- 371
- Issue
- 23
- Pages
- 2155-2166
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4481318
- OpenAlex
- W2125173296
- Cited by
- 1,928
- References
- 39
- Citations by year
- 2026: 69 · 2025: 75 · 2024: 80 · 2023: 109 · 2022: 125 · 2021: 154 · 2020: 182 · 2019: 150 · 2018: 183 · 2017: 242 · 2016: 288 · 2015: 254 · 2014: 9
- FWCI
- 181.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- BORIS (University Library Bern) (submittedVersion, other-oa)
- Open Access CRIS of the University of Bern
- Funders
- U.S. Food and Drug Administration (1r01fd003870-01, R01 FD003870)
- National Heart, Lung, and Blood Institute (R01HL057506, R37HL057506, K23HL118138)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- dual antiplatelet therapy, drug-eluting stents, coronary stenting, clopidogrel, prasugrel, thienopyridines, aspirin, stent thrombosis, major adverse cardiovascular events, bleeding risk, myocardial infarction, stroke, mortality, periprocedural bleeding, bleeding risk stratification
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Drug Administration Schedule, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Piperazines, Platelet Aggregation Inhibitors, Thiophenes, Thrombosis, Ticlopidine, Time Factors, Incidence, Myocardial Ischemia, Drug-Eluting Stents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.